Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2882586 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TDP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5989140 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TDP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2887116 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TDP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3947551 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TDP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2883779 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TDP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10347703 | 0.82 | CYP1A2 (0.38) | ALDH1A1CYP1A2CYP2C9CYP2C19KCNH2 | |
| SCHEMBL6982321 | 0.82 | CYP1A2 (0.55) | ALDH1A1TDP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9742504 | 0.79 | CYP1A2 (0.55) | ALDH1A1TDP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2891965 | 0.79 | KCNH2 (0.40) | ALDH1A1TDP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5988133 | 0.79 | KCNH2 (0.40) | ALDH1A1TDP1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394974-B2 | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-03-12 | — | — | US | disclosed |
| US-8394974-B2 | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-03-12 | — | — | US | disclosed |
| US-8394974-B2 | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-03-12 | — | — | US | disclosed |
| EP-1718629-B1 | Benzopyran compounds useful for the treatment of arrhytmia | NISSAN CHEMICAL IND LTD (JP) | 2012-12-26 | — | — | EP | disclosed |
| EP-1732929-B1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL IND LTD (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-7781483-B2 | Benzopyran compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20100069374-A1 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-7652008-B2 | 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| EP-2003135-A9 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-2003135-A2 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| US-20070299130-A1 | Benzopyran Compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-12-27 | — | — | US | disclosed |
| EP-1718629-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR THE TREATMENT OF ARRHYTMIA | Nissan Chemical Industries, Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005080368-A2 | BENZOPYRAN COMPOUND USEFUL FOR THE TREATMENT OF ARRHYTMIA | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | CBR1, CBR3, CYP2C9 | ALDH1A1 2252/4885TDP1 4038/4885CYP1A2 365/4885 |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | CYP2C19, CYP2C9, CYP1A2 | ALDH1A1 1146/4885TDP1 1794/4885CYP1A2 3/4885 |
| US-20070299130-A1 | Benzopyran Compound | NR0B1, CYP2B6, RYR2 | ALDH1A1 2971/4885TDP1 4487/4885CYP1A2 529/4885 |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | ALDH1A1 2087/4885TDP1 3969/4885CYP1A2 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.